A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

NCT ID: NCT02869438

Last Updated: 2019-10-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 233 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-11-09
• Study Completion Date: 2018-08-01

Brief Summary

The purpose of this study is to investigate the onset and maintenance of effect of benralizumab on lung function, blood eosinophils, asthma control metrics and quality of life during 12-week treatment in patients with uncontrolled, severe asthma with eosinophilic inflammation. A subset of patients will take part in body plethysmography substudy to further investigate the effect on lung function.

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: DOUBLE

Study Groups

Benralizumab arm

Benralizumab administered subcutaneously

Group Type: EXPERIMENTAL

Benralizumab

Intervention Type: DRUG

Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)

Placebo arm

Placebo administered subcutaneously

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)

Interventions

Benralizumab

Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)

Intervention Type: DRUG

Placebo

Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Written informed consent for study participation must be obtained prior to any study related procedures being performed and according to international guidelines and/or applicable European Union (EU) guidelines.

2. Female and male aged 18 to 75 years inclusively at the time of Visit 1

3. Documented current treatment with ICS and LABA for at least 30 days prior to Visit 1. The ICS and LABA can be parts of a combination product or given by separate inhalers. The ICS dose must be greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or equivalent daily. Additional asthma controller medications, eg, oral corticosteroids, long-acting antimuscarinics (LAMAs), LTRAs, theophylline etc. are allowed if they have been used for at least 30 days prior to Visit 1

4. History of at least 2 asthma exacerbations that required treatment with systemic corticosteroids (intramuscular (IM), intravenous (IV), or oral) in the 12 months prior to Visit 1. For patients receiving corticosteroids as a maintenance therapy, the corticosteroid treatment for the exacerbation is defined as a temporary increase of their maintenance dose.

5. Pre-bronchodilator (pre-BD) FEV1 of < 80% predicted at Visit 2 or Visit 3

6. ACQ-6 score ≥1.5 at Visit 1

7. Evidence of asthma as documented by airway reversibility (FEV1 ≥12% and 200 ml) demonstrated at Visit 1, Visit 2 or Visit 3. For patients entering the body plethysmography sub-study, reversibility must be demonstrated at Visit 1 or at Visit 2 only

8. Peripheral blood eosinophil count of ≥300 cells/μL assessed by central lab at Visit 1

9. Women of childbearing potential (WOCBP) must use an effective form of birth control confirmed by the Investigator. WOCBP must also have negative serum pregnancy test result on Visit 1.

Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for 12 months prior to the planned date of randomization without an alternative medical cause. The following agespecific requirements apply:

• Women <50 years old are considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone (FSH) levels in the postmenopausal range.
• Women ≥50 years old are considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.

10. All male patients who are sexually active must agree to use a double barrier method of contraception (condom with spermicide) from the first dose of IP until 16 weeks after their last dose

11. Weight of ≥40 kg

1. At least 1 of the following within 7 days prior to randomization:

• Daytime or nighttime asthma symptoms for 2 or more days;
• Rescue SABA use for 2 or more days;
• Nighttime awakenings due to asthma at least 1 night during the 7-day period

2. ACQ >0.75 at Visit 4 prior to randomization.

3. A negative urine pregnancy test in WOCBP prior to administration of IP

Exclusion Criteria

1. Clinically important pulmonary disease other than asthma (eg, active lung infection, COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome)

2. Life-threatening asthma defined as episodes requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episodes within the 12 months prior to Visit 1.

3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period

4. An upper respiratory tract infection or an asthma exacerbation that required treatment with systemic corticosteroids or an increase in regular maintenance dose of OCS during the screening/run-in period prior to randomization Visit 4

5. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

• Affect the safety of the patient throughout the study
• Influence the findings of the studies or their interpretations
• Impede the patient's ability to complete the entire duration of study

6. Known history of allergy or reaction to any component of the investigational product formulation

7. History of anaphylaxis to any biologic therapy

8. History of Guillain-Barré syndrome

9. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to standard of care therapy

10. Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study

11. Any clinically significant cardiac disease or any electrocardiogram (ECG) abnormality obtained during the screening/run-in period, which in the opinion of the Investigator may put the patient at risk or interfere with study assessments

12. History of alcohol or drug abuse within 12 months prior to the date informed consent is obtained

13. Positive hepatitis B surface antigen, or hepatitis C virus antibody serology, or a positive medical history for hepatitis B or C. Patients with a history of hepatitis B vaccination without history of hepatitis B are allowed to enroll

14. A history of known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test

15. Current smokers or former smokers with a smoking history of ≥10 pack years. A former smoker is defined as a patient who quit smoking at least 6 months prior to Visit 1

16. Current malignancy, or history of malignancy, except for:

• Patients who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the patient is in remission and curative therapy was completed at least 12 months prior to the date informed consent was obtained.
• Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained.

17. Use of immunosuppressive medication (including but not limited to: oral corticosteroids [for reasons other than asthma], methotrexate, troleandomycin, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroids or any experimental anti-inflammatory therapy) within 3 months prior to the date informed consent

18. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥1.5 times the upper limit of normal (ULN) confirmed during screening period

19. Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained

20. Receipt of any marketed (eg, omalizumab, mepolizumab etc.) or investigational biologic within 4 months or 5 half-lives prior to the date informed consent is obtained, whichever is longer

21. Receipt of live attenuated vaccines 30 days prior to the date of randomization

22. Receipt of any investigational medication within 30 days or 5 half-lives prior to randomization, whichever is longer

23. Previously received benralizumab (MEDI-563)

24. Planned surgical procedures during the conduct of the study

25. Currently breastfeeding or lactating women

26. Previous randomization in the present study

27. Concurrent enrolment in another interventional or post-authorization safety study (PASS).

28. AstraZeneca staff involved in the planning and/or conduct of the study

29. Employees of the study center or any other individuals involved with the conduct of the study or immediate family members of such individuals

1. Greater than/equal to 20% change in mean Pre BD FEV1 value at randomization Visit 4 from the mean pre BD FEV1 calculated from the pre BD FEV1 recorded at Visit 2 and Visit 3

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Reynold A Panettieri, Doctor of Medicine

Role: PRINCIPAL_INVESTIGATOR

Child Health Institute of NJ, 89 French Street, Suite 4210, New Brunswick, NJ, 08901, USA

Locations

Research Site

Scottsboro, Alabama, United States

Research Site

Gilbert, Arizona, United States

Research Site

Denver, Colorado, United States

Research Site

Miami, Florida, United States

Research Site

Tampa, Florida, United States

Research Site

Vero Beach, Florida, United States

Research Site

Winter Park, Florida, United States

Research Site

Fort Mitchell, Kentucky, United States

Research Site

Rochester, Minnesota, United States

Research Site

New Bern, North Carolina, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Oklahoma City, Oklahoma, United States

Research Site

Medford, Oregon, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Lampasas, Texas, United States

Research Site

McKinney, Texas, United States

Research Site

Curicó, , Chile

Research Site

Santiago, , Chile

Research Site

Santiago, , Chile

Research Site

Santiago, , Chile

Research Site

Bamberg, , Germany

Research Site

Darmstadt, , Germany

Research Site

Frankfurt, , Germany

Research Site

Frankfurt am Main, , Germany

Research Site

Frankfurt am Main, , Germany

Research Site

Hamburg, , Germany

Research Site

Hamburg, , Germany

Research Site

Hanover, , Germany

Research Site

Hanover, , Germany

Research Site

Hanover, , Germany

Research Site

Mainz, , Germany

Research Site

München, , Germany

Research Site

Balassagyarmat, , Hungary

Research Site

Edelény, , Hungary

Research Site

Farkasgyepü, , Hungary

Research Site

Gödöllő, , Hungary

Research Site

Hajdúnánás, , Hungary

Research Site

Komárom, , Hungary

Research Site

Miskolc, , Hungary

Research Site

Pécs, , Hungary

Research Site

Pécs, , Hungary

Research Site

Iloilo City, , Philippines

Research Site

Lipa City, , Philippines

Research Site

Manila, , Philippines

Research Site

Quezon City, , Philippines

Research Site

Cheongju-si, , South Korea

Research Site

Daegu, , South Korea

Research Site

Jeonju, , South Korea

Research Site

Seoul, , South Korea

Research Site

Seoul, , South Korea

Research Site

Seoul, , South Korea

Research Site

Seoul, , South Korea

Research Site

Seoul, , South Korea

Research Site

Seoul, , South Korea

Countries

United States; Chile; Germany; Hungary; Philippines; South Korea

Provided Documents

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Related Links

http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4080&filename=d3250c00038-csp-v1_Redacted.pdf

Protocol

http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4080&filename=d3250c00038-sap-ed-2_Redacted.pdf

SAP

Other Identifiers

2016-002094-36

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

U1111-1185-6625

Identifier Type: OTHER

Identifier Source: secondary_id

D3250C00038

Identifier Type: -

Identifier Source: org_study_id